Price
$32.1
Increased by +0.82%
Dollar Volume
2.09 M
ADR%
3.13
Earnings Report Date (estimate)
Mar 6, 23 (-0.24)
Market Cap.
468.97 M
Shares Float
12.88 M
Shares Outstanding
14.61 M
Beta
0.92
Price / Earnings
-274.36
BPR
240.16
20D Range
29.45 32.30
50D Range
27.01 32.30
200D Range
19.95 32.46
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 8, 22 -0.29
Decreased by -825.00%
-0.25
Decreased by -16.00%
Aug 3, 22 -0.20
Decreased by -144.44%
-0.23
Increased by +13.04%
May 5, 22 -0.20
Decreased by -200.00%
-0.36
Increased by +44.44%
Mar 8, 22 -0.40
Increased by +63.64%
-0.25
Decreased by -60.00%
Nov 4, 21 0.04
Increased by +108.89%
-0.21
Increased by +119.05%
Aug 5, 21 0.45
Increased by +183.33%
-0.15
Increased by +400.00%
May 6, 21 0.20
Decreased by -50.00%
-0.12
Increased by +266.67%
Mar 4, 21 -1.10
Decreased by -492.86%
-0.01
Decreased by -10.90 K%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 40.26 M
Increased by +1.84%
-4.17 M
Decreased by -848.21%
Decreased by -10.37%
Decreased by -834.68%
Jun 30, 22 39.66 M
Increased by +3.96%
-2.84 M
Decreased by -143.53%
Decreased by -7.17%
Decreased by -141.87%
Mar 31, 22 36.69 M
Increased by +7.00%
-2.93 M
Decreased by -203.35%
Decreased by -7.99%
Decreased by -196.58%
Dec 31, 21 35.82 M
Increased by +9.58%
-5.79 M
Increased by +63.00%
Decreased by -16.17%
Increased by +66.23%
Sep 30, 21 39.54 M
Increased by +24.74%
558.00 K
Increased by +108.70%
Increased by +1.41%
Increased by +106.98%
Jun 30, 21 38.15 M
Increased by +24.34%
6.53 M
Increased by +184.73%
Increased by +17.12%
Increased by +168.14%
Mar 31, 21 34.29 M
Decreased by -3.12%
2.84 M
Decreased by -51.01%
Increased by +8.28%
Decreased by -49.43%
Dec 31, 20 32.69 M
Increased by +9.79%
-15.66 M
Decreased by -486.47%
Decreased by -47.90%
Decreased by -452.00%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.